Yongcan Liu

499 total citations
9 papers, 337 citations indexed

About

Yongcan Liu is a scholar working on Molecular Biology, Cancer Research and Hematology. According to data from OpenAlex, Yongcan Liu has authored 9 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Cancer Research and 2 papers in Hematology. Recurrent topics in Yongcan Liu's work include Extracellular vesicles in disease (3 papers), RNA modifications and cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). Yongcan Liu is often cited by papers focused on Extracellular vesicles in disease (3 papers), RNA modifications and cancer (3 papers) and Cancer-related molecular mechanisms research (3 papers). Yongcan Liu collaborates with scholars based in China and United States. Yongcan Liu's co-authors include Manran Liu, Xueying Wan, Yixuan Hou, Yilu Qin, Yong Teng, Shuiqing Liu, Huan Zeng, Liping Yang, Peng‐Peng Zhu and Yan Sun and has published in prestigious journals such as Biomaterials, Cell Death and Disease and Theranostics.

In The Last Decade

Yongcan Liu

8 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yongcan Liu China	5	258	201	66	51	38	9	337
Cheng-Yi Sun China	7	225 0.9×	164 0.8×	69 1.0×	55 1.1×	20 0.5×	14	305
Samaneh Adelian Iran	10	202 0.8×	126 0.6×	84 1.3×	45 0.9×	23 0.6×	13	310
Lianhao Song China	9	179 0.7×	140 0.7×	58 0.9×	52 1.0×	28 0.7×	15	291
Hongfei Yu China	7	245 0.9×	227 1.1×	47 0.7×	39 0.8×	34 0.9×	11	321
Luo-Jiao Liang China	6	241 0.9×	185 0.9×	120 1.8×	148 2.9×	24 0.6×	7	382
Ahmed A. Moustafa United States	9	272 1.1×	171 0.9×	51 0.8×	65 1.3×	11 0.3×	14	344
Ziqin Liu China	9	192 0.7×	89 0.4×	46 0.7×	37 0.7×	22 0.6×	26	275
Chaofan Peng China	13	454 1.8×	320 1.6×	86 1.3×	32 0.6×	35 0.9×	15	544
Jun-Xian Du China	11	319 1.2×	206 1.0×	65 1.0×	70 1.4×	31 0.8×	22	420
Rujuan Bao China	8	257 1.0×	150 0.7×	92 1.4×	75 1.5×	20 0.5×	10	367

Countries citing papers authored by Yongcan Liu

Since Specialization

Citations

This map shows the geographic impact of Yongcan Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongcan Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongcan Liu more than expected).

Fields of papers citing papers by Yongcan Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongcan Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongcan Liu. The network helps show where Yongcan Liu may publish in the future.

Co-authorship network of co-authors of Yongcan Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongcan Liu. A scholar is included among the top collaborators of Yongcan Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongcan Liu. Yongcan Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Liu, Yongcan, Jun Ren, Jing Yang, et al.. (2025). Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting. Biomaterials. 317. 123091–123091. 1 indexed citations

Yan, Shu, Jun Ren, Jing Yang, et al.. (2025). NRF2 maintains redox balance via ME1 and NRF2 inhibitor synergizes with venetoclax in NPM1-mutated acute myeloid leukemia. Cancer & Metabolism. 13(1). 32–32.

Liu, Yongcan, Shu Yan, Fangfang Jin, et al.. (2025). Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia. Journal for ImmunoTherapy of Cancer. 13(7). e011148–e011148. 1 indexed citations

Ren, Jun, Junpeng Huang, Zailin Yang, et al.. (2024). Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia. Journal of Experimental & Clinical Cancer Research. 43(1). 176–176. 4 indexed citations

Wan, Xueying, Liping Yang, Yilu Qin, et al.. (2023). RGCC-mediated PLK1 activity drives breast cancer lung metastasis by phosphorylating AMPKα2 to activate oxidative phosphorylation and fatty acid oxidation. Journal of Experimental & Clinical Cancer Research. 42(1). 342–342. 23 indexed citations

Zeng, Huan, Yixuan Hou, Xinyue Zhou, et al.. (2022). Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer. Theranostics. 12(17). 7351–7370. 81 indexed citations

Liu, Shuiqing, Yan Sun, Yixuan Hou, et al.. (2021). A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. Journal of Hematology & Oncology. 14(1). 178–178. 115 indexed citations

Xi, Lei, Meixi Peng, Shuiqing Liu, et al.. (2021). Hypoxia‐stimulated ATM activation regulates autophagy‐associated exosome release from cancer‐associated fibroblasts to promote cancer cell invasion. Journal of Extracellular Vesicles. 10(11). e12146–e12146. 98 indexed citations

Wen, Siyang, Yilu Qin, Rui Wang, et al.. (2021). A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels. Cell Death and Disease. 12(5). 437–437. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact